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Human Immunodeficiency Virus Antibodies and Antigen 
in Infants Born to Seropositive Mothers 
Laura M. Dember 
1988 
The diagnosis of HIV infection in infants bom to infected mothers is difficult. 
Because of transplacental acquisition of maternal antibody all infants bom to 
seropositive mothers are Ab-positive at birth. In order to identify serologic features 
which distinguish those infants who are truly infected twenty-five infants born to 
HIV seropositive mothers were followed prospectively. At 10-25 months of 
follow-up, 3 had AIDS, 8 had signs such as growth retardation and developmental 
delay consistent with but not specific for HIV infection, and 14 were healthy. 
Using Western immunoblotting, serial serum samples from 22 of these infants and 
6 children identified after the onset of clinically evident HIV infection were tested 
for antibody to two different strains of HIV. Examination of the serial antibody 
patterns revealed that appearance of new antibody, disappearance of antibody, and 
maintenance of antibody present at birth are all associated with HIV infection. Of 
16 infants w'ho lost antibody completely, 7 either had AIDS or were thriving 
poorly. These 7 infants lost their antibody at an earlier age than those who were 
asymptomatic suggesting that rapid loss of antibody may be indicative of active 
infection. Densitometric analysis of immunoblots suggests that the half-life of 
passively acquired antibody is 38 ± 3 days. HIV core antigen (p24) was detected in 
2 of 20 infants identified prospectively, 3 of 10 children identified after onset of 
clinically evident HIV infection, and 4 of 18 mothers of children in either group. 
Four of the antigen-positive children had AIDS; the fifth had signs consistent with 
HIV infection. None of the asymptomatic children were antigen positive. Each of 
the antigen-positive mothers had a child with AIDS. These findings suggest that 
antigen detection is specific but not sensitive for symptomatic HIV infection, and 
that presence of antigen in a mother's serum may be an early marker for HIV 
infection in her child. 

INTRODUCTION 
Since 1981 46,000 cases of Acquired Immunodeficiency Syndrome (AIDS) 
have been reported in the United States1. Of these 1.4%, or 640, have been 
a 
children less than 13 years old-. Some of the pediatric cases have been attributable 
to transfusion of infected blood products. By far the majority, however, have 
occurred as a result of vertical transmission from mothers w'ho themselves have 
AIDS risk factors3. 
The etiologic agent of AIDS, previously known as human T-cell lymphotropic 
virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), or AIDS- 
related virus (ARV), and now designated human immunodeficiency virus (HIV), 
was identified in 1983-844’6. Characterization of this retrovirus at the molecular 
and biochemical levels has been rapid. The entire genome has been sequenced7’10; 
eight genes and several gene products have been identified11’16. Progress in 
understanding HTV transmission, however, especially its vertical transmission, has 
been slow. Many questions remain unanswered. For example, the rate of 
transmission from infected mother to offspring is not known, and the route of this 
transmission have not been determined. Such information is important for several 
reasons. Most obviously it will enable more effective counseling of pregnant 
women and might make possible interventions to prevent future cases of pediatric 
AIDS. In addition such information may contribute to the understanding of the 
pathogenesis of HIV infection in general. Much of what is known about the 
infectivity of other viruses, particularly hepatitis B virus, came from studies of 
maternal-fetal transmission 17d8. Because children have been exposed to and 
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harbor fewer infectious agents than adults possible cofactors important to the 
development of AIDS may be more readily discernible in children 19. 
Difficulty in acquiring information about maternal-fetal transmission of HIV 
infection has, in part, been due to the problems of diagnosing HIV infection in 
infants. Because of transplacental transfer of certain immunoglobulins the 
conventional methods of diagnosis of HIV infection in adults (antibody detection by 
ELISA or Western blot) are less useful in newborns. The duration of persistence of 
passively acquired antibody has not been established making interpretation of 
serologic findings difficult even at several months of age. Other approaches such 
as detection of IgM specific antibody, detection of viral antigen, and virus isolation 
have not yet been shown to be sensitive methods for diagnosing HIV infection in 
infants. 
This thesis reports results of HIV antibody and antigen testing in a group of 
prospectively identified infants bom to HIV infected mothers. The goal was to 
identify serologic features which distinguish infected infants. The following 
questions were addressed: 
— Does the disappearance (or appearance) of HIV antibody correlate with 
clinical outcome? 
— Does the loss of antibody to particular viral polypeptides correlate with clinical 
outcome? 
— What is the half-life of maternal antibody? 
— Is the presence of HIV antigen in a child a useful predictor of forthcoming 
disease? 




REVIEW OF THE LITERATURE 
I. Pediatric AIDS: Epidemiologic, Clinical and Immunologic Features 
In late 1983 and early 1984 four papers, one each from New York, Newark, 
Miami, and Toronto, described infants and children with a new immunodeficiency 
syndrome20-23. The clinical and immunologic features similar to those of adult 
AIDS, included failure to thrive, hepatosplenomegaly, lymphadenopathy, recurrent 
infections, reversed T4/T8 lymphocyte ratio, and depressed cell-mediated 
immunity. The common risk factors among these children appeared to be parental 
intravenous (IV) drug abuse, sexual promiscuity, and Haitian background. Only a 
few had received blood transfusions. These cases, described prior to the 
identification of the human immunodeficiency virus, were felt to support an 
infectious etiology of AIDS. Subsequent to these reports a very general definition 
of pediatric AIDS was established by the CDC24. 
The CDC case definition of pediatric AIDS has been modified twice as more 
data has been gathered and as serologic testing has been developed25’26. Current 
criteria for diagnosis of full-blown AIDS include positive HIV culture or detectable 
HIV antigen, or positive serology plus either an opportunistic infection, multiple 
serious bacterial infections, or histologically-confirmed lymphocytic interstitial 
pneumonitis (LIP). To date 640 cases of pediatric AIDS have been reported. 19% 
were either hemophiliacs or recipients of blood transfusions; almost all of the 
remainder had at least one parent with a risk factor for AIDS, most commonly IV 
drug abuse3. Some of the mothers of these children had AIDS or AIDS related 
complex (ARC); some were seropositive but asymptomatic. Several mothers, 
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asymptomatic at the time their child presented with AIDS, developed AIDS years 
later 27. It has become evident that infected mothers can give birth to more than one 
affected child, or they can give birth to both affected and unaffected children 28. 
Little evidence exists to support horizontal spread of HIV from infected children. 
Several investigators following household contacts and close caregivers of infected 
infants and children have found no seroconvertors19’29; there is only one case 
report of such an occurrence30. 
The clinical features of pediatric AIDS have been well described28’31. Almost 
all children have lymphadenopathy, hepatosplenomegaly, and failure to thrive. 
Parotid gland enlargement, seen in several early cases, actually occurs in less than 
10% of affected children31. Recurrent diarrhea, (often without an obvious 
infectious etiology), retarded psychomotor development, or other neurologic 
abnormalities occur in 10-50% 31>32. A set of craniofacial dysmorphisms including 
microcephaly, prominent, boxlike forehead, ocular hypertelorism and flattened 
nasal bridge have been described in a group of children with AIDS 33’34. This is 
not, however, a universal feature. 
Children with AIDS are extremely susceptible to bacterial infections, more so 
than their adult counterparts. The infections, typically resulting from common 
organisms such as Streptococcus pneumoniae, Neisseria meningitidis, 
Haemophilus influenzae, and Salmonella, include otitis media, pneumonia, 
cellulitis, and sepsis. One study of 60 children with AIDS found that 40% had at 
least one episode of sepsis; in many cases this was the presenting feature28. 
Opportunistic infections are also seen in pediatric AIDS. The most common include 
Pneumocystis carinii pneumonia (PCP), disseminated Mycobacterium avium 
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intracellulare (MAI) infection, disseminated cytomegalovirus (CMV), and 
mucocutaneous Candida35. Kaposi sarcoma, present in 20-33% of adults with 
AIDS, occurs rarely in the pediatric population36. 
Lung disease in pediatric AIDS is not confined to the above-mentioned 
organisms. Many children with AIDS - as many as 70% by one estimate31 - 
develop chronic lymphocytic interstitial pneumonitis (LIP) without a documenented 
etiologic agent. Chest roentenogram shows a nodular infiltrate; histologic exam 
reveals diffuse infiltration of alveolar septa and peribronchiolar areas by 
lymphocytes and plasma cells. The demonstration of Epstein Barr virus (EB V) 
nucleic acid in lung biopsy tissue and/or the marked elevation of antibody titer to the 
EBV viral capsid and early antigens in some of these patients suggest that LIP may 
represent a lymphoproliferative response to EBV infection37. Interestingly, LIP is 
extremely rare in adults with AIDS. 
The natural history of childhood AIDS has not been well defined. The 
diagnosis of AIDS is usually made after 3 months of age. The age of presentation 
in three studies ranged from 1 month to 6 years, with a mean of 5 months in one 
study38, 6 months in another study29, and a median of 18 months in yet a third 
study39. There is some suggestion that children are more susceptible than adults to 
the pathogenic effects of HIV. The incidence of transfusion associated AIDS in 
infants is six-fold that of adults40, and, as of 1986, 65% of the children with AIDS 
had died as compared to 50% of the adults with AIDS suggesting a more rapid 
course of disease31. However, in contrast to those children who develop severe 
opportunistic infection and die before two years of age, there is a group of children, 
often those with LIP, whose disease has a much more stable, indolent course-"*9. 
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Like adults, most infants and children with AIDS have impaired cell-mediated 
immunity, and many (80%) have a T4fT8 ratio less than l11. However, in contrast 
to adults, they are not usually lymphopenic: the reversed T cell subset ratio is due to 
an increase in number of T8 cells as opposed to a decrease in number of T4 cells28. 
It has been postulated that the increase in T8 cell number is due to concurrent viral 
infections (such as EBV and CMV) known to increase cytotoxic and suppressor 
lymphocytes89. 
B cell abnormalities, consisting of high immunoglobulin levels and a poor 
antibody response to challenge with new antigens, are common in pediatric AIDS. 
The polyclonal hypergammaglobulinemia, seen in 75% of pediatric AIDS81, may 
be a direct effect of HIV infection. Several investigators have shown that 
polyclonal proliferation of B cells can be achieved in vitro by adding HIV to B 
cells41"48. In general, these B cell defects precede the T cell abnormalities and are 
more pronounced. It has been postulated that this initial selectivity of the B cell 
deficiency reflects the timing of infection; i.e., the HIV infection may occur at a 
critical time in the maturation of the B cell system29. 
Other laboratory findings in pediatric AIDS include thrombocytopenia44, and 
increased incidence of autoantibody formation. Antinuclear antibodies and 
antilymphocyte antibodies have been demonstrated in both pediatric and adult AIDS 
patients27. 
II. Vertical Transmission of HIV: Route and Risk 
The most common source of HIV infection for a child is his/her mother. 
Except for a small number of transfusion-related cases45'48, which are decreasing 
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in frequency as a result of effective screening of blood products, children with 
AIDS have mothers at risk for the disease. The precise route of transmission is not 
known. Possibilities include transplacental infection, infection during passage 
through the birth canal, and postnatal infection via breast mild or close contact. 
Evidence exists for all three. Interruption of transmission from mother to child 
requires a detailed understanding of the underlying processes and the relative risks 
associated with each route. 
Evidence for intrauterine infection comes primarily from case reports of AIDS 
in infants born by Caesarian section49'50, and virus isolation from placenta and fetal 
tissues51’5^. In addition, the craniofacial abnormalities observed in some children 
with AIDS suggests an embryopathic effect of HIV. 
The evidence for infection during the birth process (exit infection) is indirect. 
The presence of IgM antibody to HIV in serum of a single infant at 4 weeks of age 
but not earlier is one example58. If the infection had occurred in utero, IgM might 
be expected to have been present at birth. The age of onset of symptoms of HIV 
infection also might reflect the time that infection occurred. One explanation for the 
relatively late onset of disease in children with LIP, and its localization to the lungs, 
is that in these children the infection was acquired during passage through the birth 
canal54. Isolation of virus from cervical and vaginal secretions of seropositive 
women also helps support this route of transmission55’56. 
Transmission of the virus after birth has been implicated in two cases of HIV 
infection in infancy57’58. Each child was bom to a mother reported to have 
acquired the infection from a postpartum blood transfusion. Since the mothers 
breastfed their children, the authors suggested breastfeeding as the possible mode 
of transmission. HIV has been isolated from the breast milk of infected women59. 
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The bulk of the evidence favors intrauterine infection and exit infection. The 
data, however, is limited. No systematic investigations have been conducted, for 
example, to determine when during gestation such transmission is most likely to 
occur. The facial dysmorphisms that have been reported suggest early effects of the 
virus; however, this embryopathy is by no means universal and does not rule out 
transmission at later stages of development. 
Estimates of the risk of HIV transmission from infected mother to offspring 
range widely. In one study 20 women were identified as HIV positive because 
AIDS developed in their previous children. The women subsequently gave birth to 
20 infants, 13 of whom (65%) developed AIDS6®, in two other studies with 
similar designs 11 of 17 (64%) and 4 of 12 (33%) infants developed AIDS29’27. 
However, because the mothers were identified on the basis of already having had a 
child with AIDS, the results of these studies cannot be extrapolated to seropositive 
women in general. Differences in the virulence of virus strains, viral load, or host 
susceptibility may change the rate of matemal-fetal transmission; studying children 
bom to women known to have already transmitted the virus to offspring may select 
for these qualities and thereby over-estimate the risk. Other studies found 
transmission rates to be less than 25%. The conclusions which can be drawn from 
these studies, are limited by the small number of subjects (three mothers) and short 
follow-up of the infants (one year) in one study61, and by observation of 
symptomatic rather than infected mothers in the other62. 
Preliminary data are available from the only study that is following large 
numbers of infants bom to HIV seropositive mothers62. At follow-ups ranging 
from 1 to 15 months (mean 6 months), 5 of 71 infants had developed AIDS or 
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ARC. An additional 4 infants had nonspecific symptoms such as failure to thrive 
and lymphadenopathy. Because diagnosis of childhood AIDS is based heavily on 
clinical symptoms, longer follow-up is necessary to determine the rate of 
transmission in this group. The initial data do suggest, however, that women who 
are symptomatic during pregnancy are more likely to transmit the virus than those 
who are asymptomatic. 
III. HIV Antibody in Infants Bom to Seropositive Mothers 
Because maternal immunoglobulins cross the placenta, all infants bom to HIV 
seropositive mothers are "positive" by ELISA and/or Western blot whether or not 
they are actually infected. Therefore, serologic methods employed routinely on 
adults for diagnosis of HIV infection are not as useful for infants. Only those 
infants who make antibody against specific HIV polypeptides not recognized by 
their mother’s serum can easily be identified as infected. This situation does not 
often occur. The earliest reported appearance of new antibody to polypeptides not 
recognized by maternal serum was at 3 months of age64. Prior to that the infant's 
Western blot pattern was identical to that of his mother. In most cases, infected 
mothers who complete a pregnancy have antibody to most or all of the HIV 
polypeptides that can be demonstrated by Western blot. Clearly this decreases the 
likelihood of identifying reactivities unique to the infant. 
Six months is sometimes cited as the age after which antibody in infant sera 
can be considered endogenous rather than that of the mother39. In fact, the length 
of persistence of maternal antibody to HIV is not known. There is only one 
published attempt to systematically determine this. The preliminary data from this 
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prospective study of children bom to HIV-positive mothers found that the length of 
persistence of antibody present at birth (assumed to be maternal) ranged from less 
than 20 weeks to greater than 11 months. The median age at loss was 10 months. 
Only 18 of the 71 children being followed had actually become seronegative by the 
time of the report. By lifetable analysis it was estimated that 25% would still be 
seropositive at 1 year of age6^. 
Unfortunately reversion to a seronegative state may not indicate absence of 
infection. Because of the immaturity of the immune system, pathogenic effects of 
HIV on the immune system, or masking of antigen by maternal antibody (as has 
been proposed for hepatitis B infection65), infants may not demonstrate a good 
antibody response. One study found that in some children with AIDS the presence 
of antibodies by Western blotting could only be shown after the use of bridging 
anti-immunoglobulin, and the children, especially the younger ones, recognized 
fewer polypeptides on Western blot than did their parents19. These children were 
identified after the onset of symptoms; it is not known whether they always had 
weakly reacting sera or whether they lost antibody as their disease progressed. 
Loss of antibody, particularly that directed against HIV core protein p24, has been 
demonstrated in adults just prior to the onset of clinical disease66"68, and in a small 
number of infants infected via blood transfusion69. 
The presence of viral specific IgM in newborn sera is the basis for diagnosis of 
many congenital infections since immunoglobulins of this class cannot cross the 
placenta. This approach has been attempted for congenital HIV diagnosis but with 
thus far limited success. The first demonstration of an IgM response to HIV 
infection was in an animal model for HIV infection70. Two of three chimpanzees 
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transiently produced anti-HIV IgM following infusions of plasma from AIDS 
patients. IgM has been found in humans as well. In one study, six of 30 adult 
patients with ARC, and nine of 52 adults at risk for HIV had IgM antibody detected 
by indirect immunoflurescence71; 5 of 65 IgG seronegative adult IV drug users 
were IgM positive by ELISA in another study72. In a third study HIV IgM was 
detected by radioimmunoassay in nine adult males at risk for infection73. The 
length of the IgM response ranged from 1 week to 38 weeks in these individuals. 
While these studies suggest a primary and sometimes long-lived IgM response to 
HIV infection and suggest that, in some instances, IgM antibody is the only marker 
of HIV infection in adults, the accuracy and sensitivity of the detection methods 
have not been rigorously investigated. This is particularly crucial with IgM assays 
because of the frequently encountered nonspecificity of IgM binding73 and the 
potential nonspecificity of anti-IgM reagents used in these assays. In only one of 
the studies73, for example, was removal of other classes of immunoglobulin 
included in the procedure. 
Attempts to identify IgM in infants have been reported as well. Four of 27 
infants bom to HIV seropositive mothers had IgM demonstrated by 
immunoblotting74. All four of these infants were greater than three months of age. 
None of 12 who were younger than 3 months had HIV IgM, and ten children 
without IgM later developed their own IgG indicating that they were, in fact, 
infected. Similarly, the infant described previously63 who, at 3 months, developed 
IgG against two polypeptides not recognized by his mother's serum, did not have 
detectable IgM on any of the 3 occasions tested (2, 3, and 4 months of age). 
Another infant from whom serial serum samples were collected every 4 weeks from 
birth to 5 months had no detectable IgM until 4 weeks. The quantity of IgM peaked 
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at 8 weeks and rapidly disappeared thereafter53. These studies suggest that the IgM 
response to HIV infection is weaker and more variable than in other congenital 
infections and that if present in infants may be very brief. 
IV. HIV Antigen Detection 
The first HIV antigen assays were developed in 198675>76. Most are similar to 
the ELISAs used for detecting antibody except that HIV antibody rather than 
antigen is used as the "capture" agent. These assays were designed initially to 
detect antigen in tissue culture and their sensitivity and specificity for detecting 
antigen in human serum has not been established. Nevertheless, data obtained thus 
far77'79 suggests that antigen detection may provide an important complement to 
antibody detection in diagnosing HIV infection and in studying its pathogenesis. 
One study found antigen in serum of 86% of 22 adult and pediatric patients 
with AIDS but in only 8% of seropositive asymptomatic adults. Of 35 patients 
who seroconverted during the study period antigen was detected in 1177. In 5 of 
11 antigen was present prior to detection of antibody. Three of eleven individuals 
remained seropositive for the entire 6-12 months of follow-up; the remaining 8 lost 
antigen but retained antibody. A second study by the same investigators found that 
of 19 persons positive for antibody to the HIV envelope protein gp41,7 lacked 
antibody to HIV core protein p24. All 7 without antibody to p24 were antigen 
positive. None of the 12 with core antibody had detectable antigen80. The findings 
of these studies together with the observed association between loss of antibody to 
p24 and progression of clinical disease66'69, suggest the following hypotheses: 1) 
viral antigen circulating in serum may precede antibody production, 2) antigen may 
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disappear during a latent or asymptomatic phase of the infection, and 3) the 
presence of antigen after seroconversion indicates worsening of disease. The 
decrease in antibody to p24 associated with both presence of antigen and 
progression of disease could be due either to exhaustion of the immune response or 
to increase in viral replication resulting in antigen excess and complete binding of 
available antibody. 
Antigen detection in congenital HIV infection is limited to 5 pediatric patients 
with AIDS included in the study described above75, and a group of 9 infants who 
had immunologic and clinical evidence of AIDS but lacked antibody by at least one 
detection method. All were antigen positive81. The data suggest that antigen 
testing should be combined with antibody assays for diagnosis of HIV infection. 
The studies do not assess the utility of antigen testing in asymptomatic children at 
risk for HIV infection, and there are no studies thus far which look for a 
relationship between presence of antigen and infectivity (such as that established for 
hepatitis B e antigen). 
V. AIDS in New Haven 
As of December 20, 1986, the incidence of AIDS in the New Haven standard 
metropolitan statistical area (SMSA) was 142 cases/million, the 12th highest 
incidence in the country. In the City of New Haven itself the incidence was 
significantly higher: 634 cases/million. This incidence is almost identical to that of 
the SMS As of New York and San Francisco. The AIDS population here is 
somewhat unique. It is disproportionately represented by women, IV drug users, 
and blacks. Twenty-nine percent of AIDS patients in New Haven SMSA are 
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women, compared to a national average of 7 percent. Sixty-one percent of the 
AIDS patients are black and 43 percent are IV drug users. Not surprisingly, given 
the large number of infected women, the pediatric AIDS population in New Haven 
is high. The earliest recognized case was a boy born in 197919. Since 1983, 
twenty-three other children with clinically-evident HIV infection have been 
identified39. An additional 54 seropositive infants are currently followed in the 





A. Infants born to HIV seropositive mothers (N = 25) 
These infants are part of a prospective study group (PSG) started at Yale-New 
Haven Hospital (YNHH) in December 1985. HIV-infected mothers were identified 
with the assistance of New Haven drug dependency units, and the YNHH 
Women's Center, newborn nursery, Newborn Special Care Unit and pediatric 
Primary Care Center. As of November 1987 the PSG consisted of 50 infants of 
such mothers; 25 were included in the current study. Serial serum samples were 
collected at birth and every 3-6 months thereafter. A total of 72 samples were 
obtained. Serum was stored at -20°C. 
B. Infants and children identified after the onset of clinical signs of HIV infection 
(N = 10) 
These infants and children, designated the Symptomatic Study Group (SSG), 
presented to YNHH with clinical signs of HTV infection. All were born to 
seropositive mothers, either IV drug users or sexual partners of IV drug users. A 
total of 21 serum samples was obtained for this study. 
C. HIV-infected mothers (N=18) 
One serum sample was obtained from each of 11 mothers of PSG infants 
(within 1 month of delivery) and from 7 mothers of SSG children. 
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II. Clinical Data 
Information regarding the clinical status of the infants and children was 
obtained from the records of the Pediatric AIDS Clinic. Each child was classifed 
into one of the following groups: 
1. Asymptomatic 
2. Thriving Poorly 
3. AIDS 
There currently is no agreed upon definition of pediatric ARC. For this study a 
child was labelled as "thriving poorly " if he/she did not meet the criteria for AIDS 
(see below) but had positive serology on at least one occasion plus any of the 
following: 
1. Growth Retardation —weight and height below 5th percentile or movement 
from one growth curve to a lower one 
2. Developmental Delay —assessed by the Denver Developmental Scale 
3. Persistent lymphadenopathy, hepatomegaly, splenomegaly or parotitis. 
4. Persistent or unexplained recurrent diarrhea 
5. More than one bacterial infection requiring hospitalization 
The CDC case definition of Pediatric AIDS2^ was used in this study. Any child 
with positive serology on at least one occasion plus either an opportunistic infection 
or biopsy-proven lymphocytic interstitial pneumonitis (LIP) was considered to have 
AIDS. 
III. HIV Infected and Uninfected Cells 
The HIV-infected cells used as sources of antigen for the Western 
immunoblots.were H9/RF2 and X50-7.8/PH1-MN. The HIV strains, RF2 and 
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PH1-MN, were isolated from a Haitain patient with AIDS (RF2) and a child with 
ARC (PH1-MN). Both strains were provided by Robert Gallo (Bethesda, MD). 
H9 cells are a subclone derived from the HT T-cell leukemia line4. X50-7 cells are 
human umbilical cord lymphocytes immortalized in vitro by EBV. They contain a 
tighdy latent complete EBV genome82. The X50-7.8 clone is particularly 
susceptible to HIV infection. Uninfected H9 and X50-7.8 cells were used as 
negative controls. Every serum was tested against a panel of antigen from both the 
infected and uninfected cells in order to distinguish adequately between reactivity to 
viral proteins and normal cell proteins. All cells were grown in RPMI 1640 plus 
10% fetal calf serum with penicillin (50 pg/ml), streptomycin (50 |ig/ml) and 
amphotericin (50 jig/ml). 
IV. Immunoblots 
Cellular extracts were prepared by harvesting cells and resuspending them in 
SDS electrophoresis sample buffer (125 mM Tris [pH 6.8], 2% SDS, 10% 
glycerol, 0.1% 2-mercaptoethanol, 0.2% 35mM phenylmethylsulfonyl fluoride, 
and bromphenol blue) at a concentration of 108 cells/ml. The extracts were 
sonicated and boiled for 5 minutes just before loading; they were electrophoresed 
overnight on 20 x 20 cm 12% acrylamide/ bis-acrylamide (30:0.8) gels at 40V. The 
proteins were then transferred from the gel to nitrocellulose filter paper at 200 mA 
for 4 hrs. The filter paper was blocked for 1 hour with "Blotto" (5% wt/vol nonfat 
dry milk, 0.01% antifoam, and 0.002% thimerosal) to prevent nonspecific 
binding. After blocking, the filters were incubated with serum (previously heated 
to 60 °C to inactivate virus) diluted 1:100 in Blotto for 1 hr at room temperature 
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(23°C). After washing (10 mM Tris, 16 mM NaCl, % Tween) the filters were 
incubated for 1 hr with 125I-labelled staphylococcal protein A (New England 
Nuclear). After a final wash the nitrocellulose filter was air-dried and exposed to 
XR O-MAT film (Eastman Kodak, Rochester, NY) for 48 hours at -20°C with 
intensifying screens. Negative blots were reexposed to film for up to 1 week. 
In order to compare relative amounts of antibodies present in different serum 
samples multiple immunoblots were prepared simultaneously using the same 
preparations of cell extracts for all blots. The incubations with serum and 125I- 
staph A were done in parallel with the same reagents. 
V. Immunoblots with Bridging Antibodies 
Several of the serum samples which were negative for antibody by immunoblot 
were retested with the use of bridging Abs in an effort to increase signal or to detect 
IgG subclasses and Ig classes that do not react with staphyloccal protein A. The 
bridging Ab was rabbit IgG fraction antibody to human light chains (Cal Biochem, 
La Jolla, CA). The nitrocellulose filter was blocked and incubated with the 
patient’s serum as usual and then for an additional 1.5 hr with the bridging antibody 
diluted 1:100 in Blotto. The filters were then incubated with iodinated staphyloccal 
protein A, which also binds well to rabbit IgG. 
VI. Determination of Antibody Half-Life 
The relative quantities of the HIV antibodies present in serial serum samples 
were determined by densitometric readings of the immunoblot bands. A Joyce- 
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Loebl densitometer was used. The log of antibody quantity (i.e., area under 
densitometer tracing) was plotted against time and antibody half-life was calculated 
according to the following equation: 
_ lQgio2 
slope 
where t m equals half-life, and slope eqUa,s:^2£»teEM. 
VII. Detection of HIV Antigen 
Sera were tested for HIV p24 antigen using two commercially available 
enzyme-linked immunoassays (Abbott Laboratories and DuPont Laboratories). All 
samples and controls were assayed in duplicate according to the instructions of the 
manufacturer. The Abbott assay was performed as follows: 200|il of sample was 
incubated overnight at room temperature with a bead coated with polyclonal human 
anti-HIV. Beads were washed with distilled water and incubated for 4 hr at 37°C 
with rabbit IgG Ab to HIV p24. Beads again were washed and incubated for 2 hr 
at 37°C with horseradish peroxidase-conjugated goat anti-rabbit IgG. After a final 
wash the beads were incubated with o-phenylenediamine for 30 minutes at room 
temperature in the dark. IN sulfuric acid was added and the A492 was read with a 
spectrophotometric plate reader. The presence or absence of HIV antigen was 
determined by comparing O.D. of sample with O.D. of HIV Ab negative serum 
from an individual with no risk factors for HIV infection. A sample was 
considered positive for antigen if its mean O.D. was greater than the negative 
control mean O.D. plus 0.050. 
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The DuPont assay was similar. Two hundred (il of sample was incubated 
overnight at room temperature with polyclonal rabbit anti-HIV p24 fixed to 
microtiter plate well. Wells were washed with a PBS/Tris solution and incubated 
with biotinylated rabbit anti-HIV p24 for 1 hr at 37 °C. The wells again were 
washed and incubated with streptavidin-horseradish peroxidase for 15 minutes at 
room temperature. O-phenylenediamine was added following a final wash. The 
wells were kept at room temperature in the dark for 30 minutes at which time 4N 
sulfuric acid was added. The A492 was read with a spectrophotometric plate- 
reader. Quantitation of p24 Ag was done by comparing the O.D. of sample with the 
O.D.s of HIV viral lysates with knowm concentrations of p24. A sample was 
considered positive if its concentration of p24 antigen was at least two times that of 




I. Clinical Findines 
As of January, 1988 the clinical status of the 25 infants in the prospective 
study group (PSG) was as follows: 3 had AIDS, 8 were thriving poorly, and 14 
were healthy. Two of the infants with AIDS had died, the third has recovered from 
P. carinii pneumonia. The most frequent sign among the children who were 
thriving poorly was growth retardation, especially poor weight gain; some children 
manifested signs of developmental delay. Recurrent diarrhea, lymphadenopathy, 
hepatomegaly, facial dysmorphism, and Neisseria meningitidis infection were also 
observed in this group. The length of follow-up ranged from 10 months to 25 
months; the median was 16 months. 
Of the 10 children in the symptomatic study group (SSG), i.e., those bom to 
HIV-infected mothers but identified only after AIDS was clincally evident, 4 have 
died. Three died between 2 and 3 years of age and one died at 6 years. 
II. Recognition of HIV Proteins on Western Immunoblot Using Sera from HTV 
Seropositive Infants 
Figure 1 shows an immunoblot of serum from a neonate bom to an HIV Ab- 
positive mother. Seven clusters of HIV polypeptides with the following molecular 
weights are recognized: 24 kDa, 41 kDa, 46/49/53 kDa (triplet), 60/61 kDa 
(doublet), 70 kDa, 96 kDa, and 120 kDa. Two other clusters with molecular 
weights of 17 kDa and 33/35 kDa (doublet) were recognized by other seropositive 
individuals. Three of these proteins have been characterized. The 24 kDa 
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polypeptide (p24), encoded by the gag gene, is a structural component of the viral 
core. The 41 kDa glycoprotein (gp41) is a transmembrane protein of the viral 
envelope and is thought to mediate fusion of susceptible host cells. The major 
envelope glycoprotein, gpl20, binds to the CD4 receptor on the host cell surface, 
thereby initating infection. In several individuals the 120 kDa glycoprotein was 
recognized when serum was reacted with X50-7.8/PH1-MN cell extract but not 
with the H9/RF2 extract. In contrast, the 46/49/53 kDa triplet was in many cases 
better recognized with the H9/RF2 antigen preparation. In Figure 1 reactions with 
cell-associated proteins can be seen in both cell lanes containing extracts from 
uninfected cells (X50-7.8 and H9). 
III. Comparison of Antibodies Present in Maternal and Neonatal Serum 
Because antibody that is present in infant serum but not in maternal serum 
would be one indicator of congenital HIV infection, immunoblots of neonatal serum 
(obtained within one month of birth) from 15 of the PSG infants were compared 
with immunoblots of corresponding maternal serum. Figure 2 shows a 
representative infant/mother pair of blots. None of the neonates had antibody to 
HIV proteins that was not present in his/her own mother's serum. 
IV. Examination of Antibody Responses in Serial Blood Samples 
A. Prospective Study Group 
In order to identify relationships between the presence (or absence) of antibody 
and clinical outcome, serial serum samples from 22 of the infants in the PSG were 
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tested side by side using immunoblots. Samples were obtained at least once prior 
to and at least once after 5 months of age. Two samples were collected from each 
of 7 infants, three samples from each of 9 infants, four from each of 4 infants, and 
five from 2 infants. The longest period of follow-up was 22 months. Table 1 
shows the specific antibodies present in each sample and their relative intensities 
(judged visually) on immunoblot. The serologic results can be divided into four 
categories: 
1. New antibodies appeared, as evidenced by either a new band or a more 
intense band. (n=l) 
2. Antibodies present at birth disappeared and no new antibody appeared. 
(n=16) 
3. Antibodies present at birth faded but were still present. (n=4) 
4. Antibodies present at birth were still present and did not decrease in 
intensity. (n=l) 
The clinical status of children belonging to each category of antibody reactivities is 
summarized in Table 2. 
Figure 3 shows the immunoblots of two of the three serial samples from the 
one child (PSG #1) who developed new antibody. Antibody to gp41 and to p70, 
not present at 4 days of age, appeared by 5 months. In addition, antibody to p24 
increased in amount. Passively acquired antibody to two of several EBV nuclear 
antigens (EBNA 1 and 2) completely disappeared by 5 months. Serum tested at 10 
months of age (blot not shown) contained the same antibodies that were present at 5 
months. The presence of new antibody is thought to be indicative of true infection. 
When last examined at 11 months the child was below the 5th percentile for height 
and weight and had delayed acquisition of motor skills (e.g. she did not bear weight 
at 9 months of age). She was classified as thriving poorly. 
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Sixteen of the children (PSG #2-16) who were seropositive at birth lost their 
antibody completely. One child developed AIDS (he was diagnosed as having PCP 
at 3 months and died at 9 months), six were thriving poorly, and nine were 
asymptomatic. The earliest that antibody disappeared was between 0 and 3 mos 
(PSG #3). The longest that antibody persisted before disappearing was 9-13 mos 
(PSG# 15). If age at loss of antibody is defined as halfway between the last 
positive sample and the first negative sample, the median age at which antibody 
disappeared was 5 months. In 5 of 7 symptomatic children who lost antibody, the 
loss occurred at or earlier than the median age of disappearance. 
Four children in the PSG, still Ab-positive at the end of the study period, 
completely lost antibody to some of the HIV proteins and had progressively 
decreasing reactivity to others. An example of this "fading" pattern is shown in 
Figure 4. One of these children (PSG #18) had AIDS and died from PCP at 8 
months, one child (PSG #19) was thriving poorly at 8 months with recurrent 
diarrhea and thrush, and the other two (PSG #16 and 17) were asymptomatic. 
Only one child (PSG #22) had a constant antibody pattern during the entire 
study period. His immunoblots are shown in Figure 5. His earliest serum, from 4 
months of age, recognized only one polypeptide cluster (p60/61). At 6 months and 
again at 10 months his reactivity was the same. This child was hospitalized 5 times 
during his first 6 months of life for diarrhea, fever, and pneumococcal sepsis. He 




B. Symptomatic Study Group 
Serial serum samples from six of the SSG children (i.e., children identified 
following clinical evidence of symptomatic HIV infection) were examined by 
Western immunoblot in an an attempt to learn what happens to the antibody 
response as disease progesses. The antibodies present in each sample are shown 
in Table 3. One patient showed strong reactivity to 7 out of 9 polypeptide clusters, 
including p24, gp41 and gp 120 on all 5 occasions tested over a two year period 
following presentation with LIP. The other subjects, 2 of whom died, had 
reactivities to fewer HIV proteins (only 1, 2, or 3 bands on immunoblot). All 5 of 
them either lost or never had reactivity to p24 during the test period, The size of 
the SSG is too small to allow correlation of immunoblot patterns with clinical 
status. 
V. Immunoblots with Bridging Antibodies 
Previous work had shown that antibody in children with AIDS may be difficult 
to detect by immunoblot and that the use of bridging anti-immunoglobulins can 
increase sensitivity Six serum samples which had been either negative or very 
weakly reactive by standard immunoblotting were retested using rabbit anti-human 
light chain as a bridging antibody. The samples were from 4 PSG infants (two of 
whom had AIDS, one of whom was thriving poorly, and one of whom was 
asymptomatic) and from 2 SSG children. The addition of bridging antibody 
increased the intensity of the bands representing cellular proteins, but did not reveal 
new reactivity to viral proteins as seen in Figure 6. 
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VI. Half-Life of Passively-Acquired Antibody 
Densitometric reading of immunoblots was used to quantitate what was 
believed to be passively-acquired antibody against HIV polypeptides. Half-life 
was calculated as described in the Methods section for the antibodies to p 17 and/or 
p60/61 in three PSG infants who had "fading antibody." These subjects were all 
asymptomatic and antigen-negative. The pi7 and p60/61 antibodies were selected 
for the measurements because the intensities of these bands were in the range that 
could be accurately read by the densitometer. The results of the half-life 
determinations are shown in Table 4. The mean of the calculated half-lives was 38 
± 2.9 days. 
VII. HIV Antigen Detection 
Studies done in adults at risk for HIV infection suggest that viral antigen may 
circulate in serum prior to the appearance of antibody and that the reappearance of 
antigen in seroposite individuals may indicate progressive disease77-80. Therefore 
we wished to learn whether the presence of antigen in serum may help identify 
those children bom to HIV Ab-positive mothers who are actually infected. The 
results of two p24 antigen detection assays are shown in Tables 5, 6, and 7, and 
summarized in Table 8. Fifty-six sera from 30 children were tested. Twenty of 
these were members of the PSG; 10 were SSG children. Eleven children had at 
least one serum sample tested by both assays, 10 had serum tested by the Abbott 
assay only, and 10 had serum tested by the DuPont assay only. Eighteen mothers 
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of these children were tested: 11 were mothers of PSG infants, 7 were mothers of 
SSG members. 
Of the 48 individuals tested, 9 (19%) had at least one antigen-positive serum 
sample. The antigen positive individuals included 5 children and 4 mothers. One 
serum sample was Ag-positive by the Abbott assay but negative by the DuPont test. 
The remainder were either positive by both or only tested by one. (Of note, the 
"discrepant" sample had an antigen concentration by the DuPont assay which was 
1.92 that of the negative control, very close to 2.00 cutoff for positivity.) 
Two (10%) of the PSG infants tested had detectable antigen. The first was 
PSG infant #7. The antigen-positive sample from 8 months of age (the only serum 
tested) was antibody negative by immunoblot. This child was bom at 34 weeks 
gestation with dysmorphic features (square head, flat face). When last examined at 
age 14 months she was small for her age (5th percentile) but otherwise 
asymptomatic. The other antigen-positive PSG infant, PSG #2, was described 
previously. He lost HIV antibody completely by 5 months and died of AIDS at 9 
months. The appearance of antigen in this child coincided with the disappearance 
of antibody. 
Three (30%) of the SSG children were antigen positive. The first was SSG 
#3, the older sibling of another Ag positive child with AIDS (PSG #2). This child 
died at 6 years from MAI infection. He was Ab positive by immunoblot; however, 
he only had antibody to one protein cluster (triplet 46/49/53) on all occasions tested. 
Another child in this family is also a member of the SSG (#5). He, however, was 
antigen negative. His clinical course has been much more indolent than his two 
siblings in that he has LIP but is doing well 2.5 years after presentation. The 
second SSG child who was Ag-positive, SSG #10, presented at 7 months of age 
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with meningococcemia, hepatosplenomegaly, and thrush. LIP was demonstrated 
by biopsy. This child developed a B cell CNS lymphoma and died of disseminated 
MAI at 31 mos. His only serum sample was antibody positive. Serum from the 
third SSG Ag-postive child (SSG #4) was positive by one assay and negative by 
the other. He was first tested for antibody at age 3 months and has maintained a 
constant pattern of weak reactivity to only two clusters of polypeptides (gp41 and 
p46/49/53). He had LIP and is growth retarded at 6 years of age. 
Four of the 17 mothers tested were also antigen-positive. One is the mother of 
two antigen positive children with AIDS (PSG #2 and SSG # 3). Another is the 
mother of antigen-positive SSG #10 described above. The third is also a mother of 
a child in the SSG (SSG #6). This child has LIP and at age 8 years is doing well on 
very small doses of steroids. The fourth antigen-positive mother gave birth to 
twins, one of whom (SSG #8) has AIDS and has been antibody-positive. The 
other twin is antibody negative and healthy at age 7 years. 
Of the 13 children (from either PSG or SSG) with AIDS who were tested for 
antigen 4 were antigen positive. None of the asymptomatic PSG children were 
antigen positive, and only one of the PSG subjects thriving poorly was antigen 
positive. Hence the test appears to be specific but not sensitive for symptomatic 
infection. Four of 8 mothers of children with AIDS had detectable antigen, while 




It was recently reported that one of every 61 infants bom in New York City is 
HIV antibody positive83. This widely publicized finding has generated much 
concern and fear as it reflects the large number of women of child-bearing age 
infected with HIV. It is not known, however, how many of their infants are 
actually infected. Of the 25 infants followed prospectively in the present study, 
only three, or 12 percent, developed AIDS during the 10-25 month follow-up 
period. Although the study was not designed to determine the risk of vertical 
transmission of HTV, this finding suggests that either the risk of transmission is 
lower than the 33-65% estimates of previous studies27’29’60, or that many infected 
children do not become ill until they are older than 1-2 years of age. Both are 
probably correct. Some early studies that determined transmission risk looked at 
infants bom to women who already had one affected child and, as explained 
previously, they very likely over-estimated the risk of transmission. On the other 
hand, although several descriptions of pediatric AIDS state that most patients 
present prior to six months of age28-31, there are several children in New Haven 
alone who did not present until 4-6 years of age, suggesting that longer follow-up 
of the 25 prospectively-identified subjects may reveal an infection rate higher than 
twelve percent. In addition, longer follow-up should clarify the clinical status of 
the 8 subjects who were "thriving poorly." These infants had signs of growth 
retardation, developmental delay and serious bacterial infections, consistent with, 
but not specific for, HIV infection. It is not clear to what extent these signs may be 
due to a poor social environment. 
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Immunoblotting was used in this study to detect antibody because it is the most 
specifc method available and because it allows identification of the individual HIV 
polypeptides recognized. Cell lines infected with two different HIV strains were 
used as antigen. This increased the ability to detect reactivity to two polypeptides 
(gpl20 and p46/49/53) each of which was more prominent using one viral strain 
than the other. A negative control - antigen prepared from uninfected cells - was 
used to distinguish between reactivity to cellular and viral proteins. This control is 
not typically included in commercial Western blotting "kits." However, previous 
work in this laboratory, indicates that many uninfected individuals have circulating 
antibodies which react with proteins that are native to the cells used to grow HIV. 
These individuals would be identified as being HIV antibody-positive if their sera 
are not tested against this negative control. 
The neonates of the PSG did not have antibodies to any polypeptides not 
recognized by their own mother's serum. Thus, as others have found, Western 
immunoblotting at birth is not usually useful in diagnosing congenital HIV 
infection. 
Serial measurements of reactivity over time revealed several different patterns 
among the infants at risk. Appearance of new antibody, disappearance (either 
complete or partial) of antibody, and maintenance of antibody were all observed. 
Follow-up to date reveals no one pattern of antibody reactivity that stands out as a 
clear marker of infection. Nonetheless, the findings do raise some interesting 
possibilities. 
Appearance of antibody to antigens not recognized at birth was seen in one 
subject by the age of 5 months. This finding, presumably indicative of infection, is 
important because it demonstrates the ability in at least some infected infants to 
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mount an antibody response against the virus. Although the antibody response in 
this case occurred in the absence of definitive clinical signs of HIV infection, it was 
accompanied by signs of poor health (growth retardation and developmental delay). 
It would thus appear that the presence of antibody does not necessarily portend a 
good outcome. 
Most of the infants lost antibody during the study period. It is likely that this 
was maternal antibody acquired in utero. The length of persistence of the antibody 
ranged from 3 months to 13 months with a median of 5 months. Assuming 
exponential decay, the length of persistence of such antibody is dependent on the 
amount transferred from the mother to her fetus and on the half-life of the antibody. 
Densitometric quantitation of fading antibodies was performed for three subjects 
and was used to estimate roughly the half-life of maternal antibody to HIV. The 
calculated half-life of 38 days is somewhat longer than the 25-30 day half-lives of 
other passively acquired antibodies such as poliomeylitis antibody84 and antinuclear 
antibody85. One potential problem with such a calculation is the possibility that the 
infants on whom it was based were, in fact, infected with HIV. In such a case 
disappearance of maternal antibody, as detected by immunoblot, might be hastened 
by the presence of circulating viral antigen. That is, antigen in the serum might 
compete with the antigen on the immunoblot for the antibody. To decrease the 
likelihood that this situation interfered with the determination of half-life, the 
antibody quantitations were conducted on asymptomatic, antigen-negative infants. 
It is also recognized that in order to accurately determine the antibody half-life a 
linear relationship between the concentration of a particular antibody in serum and 
the intensity of the corresponding band on immunoblot needs to be demonstrated. 
Knowing the half-life of maternal antibody could be quite useful in distinguishing 
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infected from non-infected infants. An infected infant might be expected to have his 
antibody disappear at either a faster or slower rate than predicted by the known half- 
life. Rapid fading might suggest high levels of circulating antigen, while slow 
fading might indicate production of antibody by the infant himself. 
Interestingly, among all infants who lost antibody, most of those who were 
thriving poorly or had AIDS lost their antibody earlier than those who were 
asymptomatic. The difference was not statistically significant, perhaps because 
some of the infants "thriving poorly" were doing so for reasons unrelated to HIV 
infection. Since the length of persistence of maternal antibody depends on the 
amount present at the outset, these rapid losers of antibody may be infants who 
received less maternal antibody in utero. For other congenital infections it is 
believed that maternal antibody has a protective, viral neutralizing effect. If this is 
the case for HTV as well, the infants who received less of this antibody moiety 
transplacentally may have a higher rate of HIV infection or a more rapid onset of 
clinical disease. 
Antibody, in general, whether passively acquired or actively produced, may 
have a protective role for the HIV-infected individual. This idea was proposed by 
other investigators in this laboratory when they found a diminished antibody 
response and more rapid onset of disease in children with AIDS compared to their 
parents19. In the present study, of all eight children with AIDS (from both the PSG 
and the SSG) only one had antibody to more than three polypeptides by the time 
clear signs of HIV infection were observed. 
A diminished antibody response in infected individuals may allow the virus to 
exert its pathogenic effects or it may reflect increased viral replication and increased 
circulating antigen. Studies of adults have demonstrated the presence of antigen in 
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serum prior to the onset of clinical signs of HIV infection80. By analogy, we 
surmised that antigen testing might also be useful in diagnosing true HIV infection 
in infants. However, antigen detection assays performed in the present study did 
not support this. Four of five antigen positive children had AIDS. This suggests 
that detectable antigen is indicative of advanced HIV infection. The one antigen- 
positive child without AIDS has signs of poor health and probably is, in fact, 
infected. However, five other children with clear clinical evidence of HIV infection 
were antigen-negative. In addition, with only one exception, all infants without 
AIDS but at risk for infection were antigen-negative. These findings imply that 
antigen assays may not be sensitive for HIV infection, and that antigen is not 
detectable as an early marker of infection. Antigen testing of mothers, on the other 
hand, may be more useful. Although there were antigen-negative mothers who had 
infected children, all of the antigen-positive mothers had children who developed 
AIDS, suggesting that the presence of antigen in maternal serum may be a marker 
for infection in her child. 
In conclusion, examination of antibody patterns and antigenemia in infants 
bom to HIV-seropositive mothers did not yield any absolute markers of HIV 
infection. However, the results do suggest the following: 1) Many infected infants 
are capable of producing antbody against HIV proteins. 2) During the first two 
years of life, production of new antibody, disappearance of antibody present at 
birth, and maintainence of antibody present at birth are all associated with HIV 
infection. 3) Complete loss of antibody by 5 months of age may be suggestive of 
active infection. 4) A rough estimate reveals that the half-life of passively acquired 
maternal antibody is 38 days. 5) The presence of HIV core antigen (p24) in serum 
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is not a sensitive measure of HIV infection in infants, but does appear to be specific 
for symptomatic infection. 6) The presence of antigen in maternal serum may be a 




















































































































































































































+ + + 




+ + + 








+ + + 
+ + + 
+ + + 












1 1 1 + 1 1 1 1 +1 
o 
























































































































> ’ t— 3 
O Cl 
E 



















































































































































+ 1111 + + | || + + 1 1 1 + 1 1 
+ + | i 






+ 1111 UNI 1 1 1 
+ + 1 1 
+ + 1 1 
<n 









1 1 1 II x + + 1 1 i i i II 1 1 
~ CO 
c iQ 








1 II 1 1 + + 1 1 1 + + 1 1 1 : i i t + ii 
o 






II 1 1 1 +1 i i i t i i + + i i 
o 
































































































































































































r-" + + | | 





+ + | | 





+ + M 1 1 + 1 1 1 1 1 1 1 1 1 
</i 














 t + 1 1 + | 1 1 X 1 : i + + | | 
o 






+ + | | + | 1 1 + i + i II 1 1 
o 














































r- r- t" 
X X cc 

















































































































































r» X + + | 






+ + 1 
+ + + 







































+ 1 1 1 1 1 l l 11 
1 








e vc r- t~~ 






 r- r- oc 
OC 00 DC 

































































































































r- + + + 
+ 1 
+ + . 
+ + 






+ + + 
+ + + 




+ + + 
+ + t 
+ ++ 
+ + i 
+ + + + 1 1 1 
C/3 <u r-H 
'-5 ^ 




+ + + 
+ + 
+ + + 




+ + + 









+ + + 
+ + 
+ + + 
+ + 1 




+ + + 
+ + 
+ + + 
+ + t 












































































Table 2. Clinical Status of PSG Children 









1. New Antibody 
Appeared 0 1 0 1 
2. Antibody 
Disappeared 9 6 1 16 
3. Antibody Fading 
But Present 2 1 1 4 
4. Antibody 
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Table 4 Determination of Antibody Half -Life 
PSG Subject* HIV Antibody 
Log[AbJ** in 
Serum Sample 1 
Log[Ab] **in 
Serum Sample 2 
Number of Days 
Between Samples 
* * * 
ll/2 
20 Pi 7 2.46 2.01 51 34 
p60/61 2.84 1.67 144 37 
21 p60/61 2.21 1.89 43 40 
15 pl 7 2.94 2.23 95 40 
Mean tj/2 = 37.8 days 




Subject numbers correspond to those in Table 3. 
Antibody (Ab) quantity was determined by densitometry of immunoblot bands. 
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Table 5 Results of Antigen Testing by Abbott and DuPont 
Assays for Prospective Study Group 
PROSPECTIVE STUDY GROUP 
PSG Sample Abbott DuPont 
Subject* Date Assay Assav 
1 11/86 — — 
2 7/86 
12/86 + + 
4/87 NT - j 
3 4/87 NT — 
4 12/86 — — 
5 6/86 NT 
9/86 — NT 
10/86 — NT 
1/87 — - 1 
6 2/86 NT 
6/86 — NT 
8/86 — NT 
12/86 — — 
7 5/87 NT + 
12 4/87 NT — 
13 6/87 NT — 
14 2/87 NT 
4/87 -- — 
15 3/87 NT — 
PROSPECTIVE STUDY GROUP 
PSG Sample Abbott DuPont 
Subject Date Assay Assay 
19 4/87 NT — 
20 9/86 NT 
2/87 — — 
21 8/86 NT 
10/86 — NT 
3/87 NT — 
22 6/87 NT — 
23 6/87 NT — 
24 3/87 NT — 
25 11/86 NT 




NT not tested 
* Subject numbers correspond to 
subjects in Table 1. Prospective Study 
Group (PSG) subjects 8, 9, 10, 11, 
16,17 and 18 were not tested for antigen. 
PSG subjects 23, 24 and 25 did not have 
serial antibody testing and are not 
included in Table 1. 
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Table 6 Results of Antigen Testing by Abbott and DuPont 
Assays for Symptomatic Study Group 
SYMPTOMATIC STUDY GROUP 
SSG Sample Abbott DuPont 
Subject* Dale Assay Assay 
1 2/85 NT 
12/86 NT — 
2 5/86 NT 
7/86 — NT 
11/86 — NT 
3 8/85 + NT 
6/86 + NT 
4 8/84 + NT 
3/87 + — 
5 8/85 ' NT 
12/86 — NT 
6 10/80 NT 
11/82 — NT 
6/84 — NT 
1/87 — NT 
7 5/87 NT — 1 
8 4/87 — — 
9 2/85 — rrr 




NT not tested 
* Subject numbers correspond to subjects in Table 3. Symptomatic 
Study Group (SSG) subjects 7-10 did not have serial antibody testing 
and are not included in Table 3. 
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Table 7. Results of Antigen Testing by Abbott and DuPont Assays 
for Mothers of Prospective and Symptomatic Study Groups 
MOTHERS OF CHILDREN IN 








2 — NT 
3 + + 
4 — NT 
5 + + 
6 + NT 
8 + + 
9 — — 
10 + NT 
MOTHERS OF CHILDREN IN 








1 — — 
2 + + 
6 — — 
13 NT — 
14 — — 
15 — — 
20 — — 
21 — NT 
23 — NT 
24 NT — 




NT not tested 
* Subject numbers correspond to PSG 
and SSG subjects in Tables 3, 4 and 5. 
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Table 8. Results of p24 Antigen Assay in PSG and SSG Children 
Number of Children or Mothers with 














PSG Children 0/2 1/9 1/9 2/20 (10) 
SSG Children 3/7 0/1 0/2 3/10 (30) 
PSG Mothers 0/1 0/3 1/7 1/11 (9.1) 




FIGl'RE 1. HIV ANTIBODY DETECTION ON A WESTERN IMMUNOBLOT. 
Serum from a neonate bom to an HIV-antibody postive mother was reacted with an 
mmunoblot containing extracts from 4 different cell lines: X50-7.8 (derived from 
EBY-transformed B cells), X50-7.8/PH1-MN (X50-7.8 cells infected with HIV 
strain PH1-N1N), H9 (derived from a T cell leukemia line), and H9/RF2 (H9 cells 
infected with HIV strain RF2). The EBV nuclear antigens, EBNA 1 and EBNA 2, 
are present in the X50-7.8 and X50-7.8/PH1-MN extracts. Note multiple 
reactivities to cell-associated proteins in the uninfected cell lines (X50-7.8 and H9) 
anti a wide spectrum of reactivities to a full array of viral polypeptides in the 
infected cell lines (X50-7.8/PH1-MN and H9/RF2). Numbers on the left are 
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FIGURE 2 COMPARISON OF HIV ANTIBODIES IN SERUM OF AN 
INFANT AND HIS INFECTED MOTHER. 
The particular HIV antibodies (as well as their relative quantities) present in the 






FIGURE 3. APPEARANCE OF NEW ANTIBODIES TO HIV IN AN INFANT 
BORN TO AN HIV ANTIBODY-POSITIVE MOTHER. 
During the first 5 months of life there has been marked intensification of the 
antibody response to p24 and acquisition of antibody to gp41 and p70. There has 
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FIGURE 4. PROGRESSIVE LOSS OF ANTIBODIES TO HIV IN AN INFANT 
BORN TO AN HIV ANTIBODY-POSITIVE MOTHER. 
Over the first 6 months of life reactivities to the 9 HIV polypeptide clusters have 
diminished or become undetectable. 
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FIGURE 5. CONSTANT PATTERN OF HIV ANTIBODY IN AN INFANT 
BORN TO AN HIV ANTIBODY-POSITIVE MOTHER. 
This infant with full-blown AIDS has reactivity to only one cluster of HIV 
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FIGURE 6. THE USE OF BRIDGING ANTIBODY WITH WEAKLY 
REACTIVE SERUM. 
The addition of rabbit anti-human light chain immunoglobulin following incubation 
of the immunoblot with serum does not reveal reactivities to any HIV polypeptides 
which were not detected without bridging antibody. The bands at 30-35 kDa in the 
X50-7.8 and X50-7.8/PH1-MN lanes of the bridging Ab immunoblot reflect 




bridging antibody bridging antibody 
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